Back to News
Market Impact: 0.25
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Source: marketbeat.com
Healthcare & BiotechTechnology & InnovationCorporate Guidance & Outlook
Editas Medicine reiterated its strategy as an in vivo gene-editing company and remains on track to dose patients in 2026 in a clinical study of EDIT-401, its lead LDL-cholesterol-lowering program. The update supports the company’s development timeline but provides no new clinical efficacy or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
EDIT0.45
More News
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- EQT becomes the nation’s leading natural gas ‘juggernaut’ with a $13B deal as data center, export demand surges
- Meta announces $95 billion stock offering to fund AI expansion
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Apple says it will replace iPhone Duo units showing screen problems
- Japan Exchange Group H1 profit jumps 65% on soaring trading activity